

Sharma V, Sharma PC, Kumar V. Indolizine derivatives as phosphodiesterase IV inhibitors: development and validation of pharmacophore models. *Bull. Pharm. Res.* 2016;6(2):68-73.

References (30):

1. Balasubramanian R, Vijaya Gopal R. Design and *in silico* analysis of ring-A monosubstituted chalcones as potential anti-inflammatory agents. *Bull. Pharm. Res.* 2012;2(2):70-7.
<https://www.appconnect.in/app/journalUploads/dp-5-4.pdf>
2. Banner KH, Trevethick MA. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. *Trends Pharmacol. Sci.* 2004;25(8):430-6.
<http://www.ncbi.nlm.nih.gov/pubmed/15276712>
3. Bansal H, Sharma A, Sharma V, Kumar V. Pharmacophore modeling studies on xanthenes as monoamine oxidase-A inhibitors. *Bull. Pharm. Res.* 2011;1(1):15-21.
<https://www.appconnect.in/wp-content/uploads/2012/01/ReprintBPR003.pdf>
4. Bäumer W, Hoppmann J, Rundfeldt C, Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. *Inflamm. Allergy Drug Targets* 2007;6(1):17-26.
<http://www.ncbi.nlm.nih.gov/pubmed/17352685>
5. Castro A, Jerez MJ, Gil C, Martinez A. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. *Med. Res. Rev.* 2005;25(2):229-44.
<http://www.ncbi.nlm.nih.gov/pubmed/15514991>
6. Chen S, Xia Z, Nagai M, Lu R, Kostik E, Przewloka T, Song M, Chimmanamada D, James D, Zhang S, Jiang J, Ono M, Koya K, Sun L. Novel indolizine compounds as potent inhibitors of phosphodiesterase IV (PDE4): structure-activity relationship. *Med. Chem. Commun.* 2011; 2(3):176-80.
<http://pubs.rsc.org/en/Content/ArticleLanding/2011/MD/c0md00215a#!divAbstract>
7. Ducrot P, Andrianjara CR, Wrigglesworth R. CoMFA and CoMSIA 3D-quantitative structure-activity relationship model on benzodiazepine derivatives, inhibitors of phosphodiesterase IV. *J. Comput. Aided Mol. Des.* 2001;15(9):767-85.
<http://www.ncbi.nlm.nih.gov/pubmed/11776290>
8. Gaurav A, Singh R. Pharmacophore modeling, 3DQSAR, and docking-based design of polysubstituted quinolines derivatives as inhibitors of phosphodiesterase 4, and preliminary evaluation of their anti-asthmatic potential. *Med. Chem. Res.* 2014;23(12): 5008-30.
<http://link.springer.com/article/10.1007/s00044-014-1048-3>

9. Gloerich M, Bos JL. Epac: defining a new mechanism for cAMP action. *Annu. Rev. Pharmacol. Toxicol.* 2010;50:355-75.
<http://www.ncbi.nlm.nih.gov/pubmed/20055708>
10. Goyal I, Kumar V. Pharmacophore modeling studies on aryl thioxothiazolidinones as ADAMTS-5 (Aggrecanase-2) inhibitors. *Der Pharma Chem.* 2011;3(2):448-59.
<http://derpharmachemica.com/vol3-iss2/DPC-2011-3-2-448-459.pdf>
11. Haikala H, Kaheinen P, Levijoki J, Lindén IB. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. *Cardiovasc. Res.* 1997;34(3):536-46.
<http://cardiovascres.oxfordjournals.org/content/34/3/536.long>
12. Han MH, Bolanos CA, Green TA, Olson VG, Neve RL, Liu RJ, Aghajanian GK, Nestler EJ. Role of cAMP response element-binding protein in the rat locus ceruleus: regulation of neuronal activity and opiate withdrawal behaviors. *J. Neurosci.* 2006;26(17):4624-9.
<http://www.ncbi.nlm.nih.gov/pubmed/16641242>
13. Hofer AM, Lefkimmiatis K. Extracellular calcium and cAMP: second messengers as “third messengers”? *Physiology* 2007;22:320-7.
<http://www.ncbi.nlm.nih.gov/pubmed/17928545>
14. Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. *Drug Discov. Today* 2005;10(22):1503-19.
<http://www.ncbi.nlm.nih.gov/pubmed/16257373>
15. Jeffery P. Phosphodiesterase 4-selective inhibition: novel therapy for the inflammation of COPD. *Pulm. Pharmacol. Ther.* 2005;18(1):9-17.
<http://www.ncbi.nlm.nih.gov/pubmed/15607122>
16. Kaur P, Sharma V, Kumar V. Pharmacophore modelling and 3D-QSAR studies on N³-phenylpyrazinones as corticotrophin-releasing factor-1 (CRF₁) receptor antagonists. *Int. J. Med. Chem.* 2012;(2012):1-13. (Article ID 452325)
<https://www.hindawi.com/journals/ijmc/2012/452325/>
17. Kaushik U, Sharma V, Kumar V. Computation of pharmacophore models for the prediction of mitogen-activated protein kinase activated protein kinase-2 inhibitory activity of pyrrolopyridines. *Med. Chem. Res.* 2012;21(11):3777-84.
<http://link.springer.com/article/10.1007/s00044-011-9910-z>
18. Kumar V. Topological models for the prediction of tyrosine kinase inhibitory activity of 4-anilinoquinazolines. *Bull. Pharm. Res.* 2011;1(2):53-60.
<https://www.appconnect.in/wp-content/uploads/2012/01/ReprintBPR023.pdf>
19. Maestro, Version 8.5, Schrodinger, LLC, NY2008.

20. Moore AR, Willoughby DA. The role of cAMP regulation in controlling inflammation. *Clin. Exp. Immunol.* 1995;101(3):387-9.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1553238/pdf/clinexpimmunol00222-0005.pdf>
21. Muñoz E, Zubiaga AM, Meroz M, Sauter NP, Huber BT. Cholera toxin discriminates between T helper 1 and 2 cells in T cell receptor-mediated activation: role of cAMP in T cell proliferation. *J. Exp. Med.* 1990;172(1):95-103.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2188173/pdf/je172195.pdf>
22. O'Donnell JM, Zhang HT. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). *Trends Pharmacol. Sci.* 2004;25(3):158-63.
<http://www.ncbi.nlm.nih.gov/pubmed/15019272>
23. Oger S, Mehats C, Dallot E, Cabrol D, Leroy MJ. Evidence for a role of phosphodiesterase 4 in lipopolysaccharide-stimulated prostaglandin E2 production and matrix metalloproteinase-9 activity in human amniochorionic membranes. *J. Immunol.* 2005;174(12):8082-9.
<http://www.ncbi.nlm.nih.gov/pubmed/15944316>
24. PHASE, Version 3.0, Schrodinger, LLC, NY2008.
25. Rani P, Kumar V. Development of pharmacophore models for predicting HIV-1 reverse transcriptase inhibitory activity of pyridinone derivatives. *Pharm. Chem. J.* 2011;45(1):36-42. <http://link.springer.com/article/10.1007/s11094-011-0556-4>
26. Sharma V, Wakode SR, Lather V, Mathur R, Fernandes MX. Structure based rational drug design of selective phosphodiesterase-4 ligands as anti-inflammatory molecules. *Bull. Pharm. Res.* 2011;1(2):33-40.
<https://www.appconnect.in/wp-content/uploads/2012/01/ReprintBPR020.pdf>
27. Sharma V, Kumar V. Efficient way of drug designing: a comprehensive review on computational techniques. *Bull. Pharm. Res.* 2014;4(3):118-23.
<http://journal.appconnect.in/wp-content/uploads/2015/01/Reprintbpr1011.pdf>
28. Sharma V, Kumar V. Indolizine: a biologically active moiety. *Med. Chem. Res.* 2014;23(8):3593-606. <http://link.springer.com/article/10.1007/s00044-014-0940-1>
29. Spina D. The potential of PDE4 inhibitors in respiratory disease. *Curr. Drug Targets Inflamm. Allergy* 2004;3(3):231-6. <http://www.ncbi.nlm.nih.gov/pubmed/15379590>
30. Sutherland EW, Robison GA, Butcher RW. Some aspects of the biological role of adenosine 3', 5'-monophosphate (cyclic AMP). *Circulation* 1968;37(2):279-306.
<http://www.popline.org/node/575311>